ABSTRACT
Background: Adolescent obesity has become alarming health problem reaching epidemic levels world wide,Covid 19 further worsened this scenario. Adolescent obesity is a multifaceted disease with serious immediate, intermediate and long-term consequences on both physical and mental health. So, if not intervened, It could transform into major health problem,there by posing economic challenges for future generations. So, its important to know the risk factors associated.There is limited research relating risk factors, vitamin d status and covid 19 impact.so our study is aimed at this. Methodology: This is a Cross-sectional Observational study conducted in the department of pediatrics MMCHRI, among 100 children included by convenience sampling method, aged 10 to18 years for a period of 1 year during April 2021-april 2022. Result(s):In our study of 100 study participants 75 were aged 10 to 14 years and 25 in 15 to 18 years. Our studies showed that high screen time contributed 76 %,sedentary life style 72 % along with fatty food 70 % consumptions are the major risk factors contributing to obesity. 62 % had vitamin deficiency. Conclusion(s): Our study showed high screen time, sedentary life style along with fatty food consumption are the most important risk factors. COVID-19 pandemic evoked major lifestyle changes including indoor stay reducing out door activity. Schools closed increased online classes further increasing screen time. There was vitamin D deficiency in majority of adolescents in our study. So primary prevention methods should be aimed at educating the child and family and encouraging appropriate diet and exercise from young age. Secondary prevention is by preventing the child from unhealthy habits.Due to the serious implications,effective treatments are urgently needed. Lifestyle interventions represent the recommended therapy. Copyright © 2022 Wolters Kluwer Medknow Publications. All rights reserved.
ABSTRACT
Objective: A longitudinal study (NeuCovid) was created at UC San Diego to compare the long-term neurological outcomes of SARS-CoV-2 infection in two cohorts, patients with and without prior neurologic disease. Background: While cross-sectional analyses have demonstrated the prevalence of neurological symptoms in the Post-Acute Sequelae of SARS-CoV-2 infection (PASC), the evolution of these symptoms over time has not yet been well-described. Design/Methods: Participants with neurological symptoms post-acute infection with SARS-CoV-2 were recruited. Team members conducted assessments including a detailed SARS-CoV-2 infection history, neurologic review of systems (scored on 10-point severity scale), neurologic exam, MoCA exam, and self-reported neuropsychiatric questionnaires, at baseline (conducted after acute infection resolved) and at 3-,6-, and 12-month follow-ups. As appropriate, participants were referred for imaging and neuropsychological testing. We report 6-month data, but 12-month data will be available in 2022. Results: 61 participants (69% female, mean age 50.2 years) were enrolled, 18 with prior known neurological disease. Acute COVID-19 disease severity was largely described as mild (44.4%) or moderate (48.1%). To date, 27 participants (74% female, mean age 52.6 years) completed baseline and 6-month follow-up visits. At baseline, the most common symptoms included fatigue (85.2%), headaches (74.1%), memory impairment (59.3%), insomnia (55.6%), and decreased concentration (48.1%). Complete symptom resolution was reported in 33.3% at 6-month follow-up. In the remaining participants at 6 months, persistent memory impairment (68.8%), decreased concentration (61.5%), fatigue (52.2%), insomnia (46.7%), and headache (45.0%) were reported. Average severity score decreased for fatigue (69.4%), headache (64.3%), insomnia (51.3%), decreased concentration (47.6%), and memory impairment (38.6%). Average MoCA scores improved from baseline (n=19, 26.4 to 28.0). Conclusions: Early in neuro-PASC, fatigue and headache were the most common reported symptoms. At 6-month follow-up, memory impairment and decreased concentration were most prominent. Only a third of participants had complete resolution of neuro-PASC symptoms at 6 months.